NASDAQ · GH
Guardant Health, Inc.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
Loading market information…
NASDAQ · CSTL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Castle Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Castle Biosciences, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Castle Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 5, 2025 | -$0.90-1,025.0% vs estimate | $87.20M+8.57% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.32+900.0% vs estimate | $86.31M+2.89% vs estimate |
|---|
| Q3 2024 | Nov 4, 2024 | $0.08+233.33% vs estimate | $85.78M+6.46% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $38.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$52.17+$1.86 (+3.7%)
Veracyte, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.35% below the high.
$17.93-$0.06 (-0.33%)
NeoGenomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.02% below the high.
$15.93-$0.08 (-0.47%)
Personalis, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$6.67+$0.04 (+0.6%)
Myriad Genetics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.41% below the high.
$24.72+$1.86 (+8.14%)
Biodesix, Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.68% below the high.
$12.86-$0.58 (-4.32%)
Freenome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 26.51% below the high.
$3.03-$0.11 (-3.5%)
bioAffinity Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.25% below the high.
